Advertisement

Klinische Wirksamkeit von Famotidin: Ein Überblick

  • B. Simon
  • H.-G. Dammann
  • P. Müller
Conference paper
  • 12 Downloads

Zusammenfassung

Der Histamin-H2-Rezeptorantagonist Famotidin wurde 1985 in Japan zur Behandlung des peptischen Ulcusleidens eingeführt. Inzwischen ist er in vielen europäischen Ländern sowie in den Vereinigten Staaten von Amerika verfügbar. Die folgende Übersicht beschäftigt sich mit den Ergebnissen international durchgeführter Studien zur Wirksamkeit von Famotidin bei verschiedenen säurebedingten Erkrankungen des oberen Gastrointestinaltraktes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Gitlin N, McCullough A J, Smith J L, Mantell G, Berman R (1987): A multicenter, double-blind, randomized, placebocontrolled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology 92, 48 – 53PubMedGoogle Scholar
  2. 2.
    Bianchi-Porro G, Dicenta C, Cook Th, Humphries T J (1987): Review of unextensive world-wide study of a new H2-receptor antagonist famotidine as compared to ranitidine in the treatment of acute duodenal ulcer. Journ of Clin Gastronoenterol 9 (Suppl 2), 14 – 18CrossRefGoogle Scholar
  3. 3.
    Rodrigo L, Viver J, Conchillo F, Barrio E et al (1987): A multicentric, randomized, double-blind study comparing famotidine versus Cimetidine in the treatment of active duodenal ulcer disease. Ital J Gastroenterol 19 [Suppl 3]: 67Google Scholar
  4. 4.
    Pajares J, Pique J, Guardia J et al (1987): A multicenter, randomized, double-blind study comparing famotidine versus ranitidine in the treatment of active duodenal ulcer disease. Ital J Gastroenterol 19 [Suppl 3]: 68Google Scholar
  5. 5.
    Dobrilla G, De Pretis G, Piazzi L et al (1987): Comparison of oncedaily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study. Scand J Gastroenterol 22 [Suppl 134]: 21 – 28CrossRefGoogle Scholar
  6. 6.
    Mann S G, Cottrell J (1987): Single night-time dosis of famotidine and Cimetidine in duodenal ulcer: A double-blind comparative study. Ital J Gastroenterol 19 [Suppl 3]: 68Google Scholar
  7. 7.
    Texter E C, Navab F, Mantell G, Berman R (1986): Maintenance therapy of duodenal ulcer with famotidine. A multicenter United States study. Amer J Med 81 [Suppl 4B]: 25 – 32PubMedCrossRefGoogle Scholar
  8. 8.
    Stadelmann O, Groh E (1986): Rezidivprophylaxe der Ulcus-duodeni- Erkrankung mit Famotidin. In: Simon B, Bianchi Porro G, Dammann H G, (Hrsg) Famotidin. Ein Fortschritt in der Therapie säurebedingter Erkrankungen. Thieme, Stuttgart, S, 71 - 76Google Scholar
  9. 9.
    Dammann H G, Walter T. A, Hentschel E, Müller P, Simon B (1987): Famotidine: Proven once-a-day treatment for gastric ulcer. Scand J Gastroenterol 22 [Suppl 134]: 29 – 33CrossRefGoogle Scholar
  10. 10.
    Humphries T et al (1988): Clinical experience with famotidine 40 mg at night in the acute treatment of benign gastric ulcer. United States Data (in press)Google Scholar
  11. 11.
    Martin L, Ruiz-Capellan R, Dicenta C (1987): A randomized, doubleblind study comparing famotidine with ranitidine in the treatment of benign gastric ulcers. Ital J Gastroenterol 19 [Suppl 3], 66Google Scholar
  12. 12.
    Rodrigo M, Castro J, Pleguezuelo J et al (1987): A randomized doubleblind study comparing famotidine with cimetidine in the treatment f benign gastric ulcers. Ital J Gastroenterol 19 [Suppl 3]: 66Google Scholar
  13. 13.
    Howard J M, Collen M J, Cherner J A et al (1985): Famotidine: An effective H2-antagonist for the therapy of Zollinger Ellison syndrome (ZES). Gastroenterology 88: 1026 – 1033PubMedGoogle Scholar
  14. 14.
    Sekiguchi T, Nishioka T, Kogure M et al (1987): Once-daily administration of famotidine for reflux esophagitis. Scand J Gastroenterol 22 [Suppl 134]: 51–54CrossRefGoogle Scholar
  15. 15.
    Saigenji K, Fukotomi H, Nakazawa S (1987): Famotidine: Postmarketing clinical experience. Scand J Gastroenterol 22 [Suppl 134]: 34 – 40CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • B. Simon
  • H.-G. Dammann
  • P. Müller

There are no affiliations available

Personalised recommendations